Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into an agreement with US firm Syncromune, an innovative pharma company focused on the development of next-generation tumor immunotherapies via intratumoral delivery. The collaboration aims to advance the development and commercialization of intratumoral immunotherapy based on Syncromune’s Syncrovax technology, a next-generation individualized tumor therapy used to optimize intratumoral immunotherapy for the treatment of metastatic solid tumors.<\/p>\n\n\n\n
Agreement Details<\/strong>
Syncromune will obtain exclusive global development and commercialization rights to intratumoral immunotherapy comprised of Eucure’s YH002 and other active ingredients, used in combination with Syncrovax. Eucure\/Biocytogen will retain all global rights to YH002 and other active ingredients, with the exception of Syncrovax. Syncromune will pay Eucure \u201chundreds of millions\u201d of US dollars in total, including an upfront cash payment based on the clinical value of the antibody molecule, development and regulatory milestone payments, sales commission, and other commercial uses of Syncrovax-based combination therapy. Eucure will be responsible for drug manufacturing and supply, while Syncromune will take charge of product clinical development and commercialization.<\/p>\n\n\n\n